Tonghua Dongbao Pharmaceutical (600867.SH): Selective cyclooxygenase-2 (COX-2) inhibitor Etoricoxib tablets granted market approval.

Tonghua Dongbao Pharmaceutical (600867.SH) announced that the company has recently received the approval and issuance of the drug registration certificate for Etoricoxib Tablets by the National Medical Products Administration. Upon review, the Etoricoxib Tablets meet the relevant requirements for drug registration, and have been approved for registration and issued the drug registration certificate. It is reported that Etoricoxib Tablets are a new generation of selective cyclooxygenase-2 (COX-2) inhibitors, with anti-inflammatory, analgesic, and antipyretic effects. Compared to traditional drugs, they have fewer gastrointestinal adverse reactions, do not contain sulfonamide groups, and have a higher safety profile for patients allergic to sulfonamides. Etoricoxib is widely used in clinical practice for conditions such as osteoarthritis, primary dysmenorrhea, and acute gouty arthritis, and is currently the only COX-2 inhibitor approved for the treatment of acute gouty arthritis in China.